EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Vascular Toxicities of Cancer Therapies: 2025 Update

Teodora Donisan, Dinu V Balanescu, Jun-Ichi Abe iD, Amir Lerman iD, Cezar A Iliescu iD, Joerg Herrmann iD

Arteriosclerosis, Thrombosis, and Vascular Biology · 2026

DOI: 10.1161/atvbaha.125.319867 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2026. Verfasst von Teodora Donisan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.D., D.V.B., A.L., J.H.). Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents, Vascular Diseases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 231 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NHLBI NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advances in cancer therapies have transformed many malignancies into chronic or manageable conditions, but have been linked to adverse, including cardiovascular, events. Vascular toxicities associated with cancer treatment range from abnormal vasoreactivity to accelerated atherosclerosis, arterial thrombotic events, vasculitis, and arterial aneurysms or dissections. 5-fluorouracil and VEGF (vascular endothelial growth factor) inhibitors are the agents most commonly linked to abnormal vasoreactivity, whereas BCR-ABL (breakpoint cluster region–Abelson murine leukemia viral oncogene homolog) inhibitors and immune checkpoint inhibitors have been associated with accelerated atherosclerosis. Arterial thrombotic events are seen with VEGF and BCR-ABL inhibitors as well as platinum drugs. Vasculitis emerged with the use of immune checkpoint inhibitors, and arterial aneurysms and dissections with VEGF inhibitors. Radiation therapy can lead to several of the outlined vascular toxicities. This review comprehensively explores the mechanisms of vascular complications associated with chemotherapy, targeted therapies, immunotherapies, and radiation therapy. Key contributors include endothelial injury and dysfunction, oxidative stress, and inflammation. An understanding of the mechanisms of vascular toxicities may facilitate optimal treatment and preventive strategies in patients with cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAntineoplastic AgentsVascular DiseasesHumansRisk FactorsImmune Checkpoint InhibitorsAnimalsImmunotherapy

Stichwörter der Autor:innen

aneurysmfluorouracilimmune checkpoint inhibitorsneoplasmsvasculitis

Substanzen

Antineoplastic AgentsImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.D., D.V.B., A.L., J.H.).
  • Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston (J.-i.A., C.A.I.).

ORCID-Profile: Jun-Ichi Abe, Amir Lerman, Cezar A Iliescu, Joerg Herrmann

Förderung

  • NCI NIH HHS
  • NHLBI NIH HHS
  • NIAID NIH HHS

Zitieren

APA

Donisan, T., Balanescu, D. V., Abe, J. I., Lerman, A., Iliescu, C. A., & Herrmann, J. (2026). Vascular Toxicities of Cancer Therapies: 2025 Update. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.125.319867

Vancouver

Donisan T, Balanescu DV, Abe JI, Lerman A, Iliescu CA, Herrmann J. Vascular Toxicities of Cancer Therapies: 2025 Update. Arteriosclerosis, Thrombosis, and Vascular Biology. 2026. doi:10.1161/atvbaha.125.319867

BibTeX
@article{Donisan2026,
  author = {Donisan, Teodora and Balanescu, Dinu V and Abe, Jun-Ichi and Lerman, Amir and Iliescu, Cezar A and Herrmann, Joerg},
  title = {Vascular Toxicities of Cancer Therapies: 2025 Update},
  journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
  year = {2026},
  doi = {10.1161/atvbaha.125.319867}
}
Kostenlos starten →